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arrays were coupled to both the front- and back-surfaces of 
the crystal (DSR configuration). The spatial-, time- and 
energy-resolutions of both configurations were measured.  
Furthermore, two detector modules containing 4 BSR 
monolithic scintillator detectors each were mounted in a 
“table-top gantry” setup allowing the emulation of a full PET 
ring of arbitrary diameter using only 2 detectors in a step-
and-shoot acquisition approach. Three-dimensional (3D) 
phantom images were acquired with both of the BSR 
detectors rotating at a radius of 35 cm from the center of the 
field-of-view. 
Results: In conventional BSR configuration, a detector spatial 
resolution of ~1.7 mm FWHM and a DOI resolution of ~3.7 mm 
FWHM was obtained, averaged over the entire detector area. 
In DSR configuration, a spatial resolution of ~1.1 mm FWHM 
was achieved in combination with a depth-of-interaction 
(DOI) resolution of ~2.4 mm FWHM. The energy resolution 
was ~10% in both detectors. The coincidence resolving time 
(CRT) in BSR and DSR configurations were ~215 ps FWHM and 
~147 ps FWHM, respectively.  
Conclusions: Monolithic scintillator detectors based on dSiPMs 
are promising for PET applications in which high spatial 
resolution, TOF resolution, and detection efficiency are 
required, all at the same time. Compared to BSR, the DSR 
configuration significantly improves the time-, spatial- and 
DOI resolutions of the detector. At the conference, first 
images obtained with BSR detectors in a TOF-PET setup 
representative of a 70 cm diameter clinical scanner will be 
presented. 
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Purpose: Proton minibeam radiotherapy aims to minimize 
normal tissue damage in the entrance channel while keeping 
tumor control through a homogeneous tumor dose due to 
channel widening with increasing track length. Side effects of 
proton minibeam irradiation were examined in an in-vivo 
mouse model to account for immune system, vasculature and 
higher complexity. Here, we report on our comparative study 
of minibeam and broad beam irradiation in the ear of Balb/c 
mice, to prove this hypothesis of reduced adverse effects in 
normal tissue. 
Methods: At the ion microprobe SNAKE, 20 MeV protons were 
administered to the right ear of 2-3 months old, female 
Balb/c mice, using an average dose of 60 Gy in a field of 7.2 
x 7.2 mm2 in the central part of the ear, in two irradiation 
modes, homogeneous and minibeams. The 4 x 4 minibeams of 
180 x 180 µm2 size were set in a distance of 1.8 mm, 
resulting in a dose of 6000 Gy in the channels, but with 
negligible dose in between. Inflammatory response, i.e. ear 
swelling and skin reactions were monitored for 90 days 
following irradiation, as well as genetic damage and release 
of inflammatory proteins. 
Results: No ear swelling or other skin reaction was detected 
after the minibeam irradiations, while significant ear swelling 
(up to 4-fold), erythema and desquamation (crust formation) 
developed in homogeneously irradiated ears 3-4 weeks after 
irradiation. Loss of hair follicles was only detected in the 
homogeneously irradiated fields after 4-5 weeks. 
Conclusion: Our results prove that proton minibeam 
radiotherapy leads to reduced side effects compared to 
conventional broad beam irradiation and could become an 
option in clinical proton and/or heavy ion therapy. 
Supported by the DFG Cluster of Excellence: Munich-Centre 
for Advanced Photonics. 
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Purpose: The Local Effect Model (LEM)1,2 and the Giant-Loop 
Binary-Lesion (GLOBLE) model3 both are based on the analysis 
of DSB distribution within the cell nucleus and particularly 
focus on DNA lesion clustering  properties with respect to the 
nanometer level as well as higher-order chromatin structure. 
According to this concept, radiation effects are uniquely 
determined by the number and microscopic spatial 
distribution of DSB. Here we demonstrate that this universal 
concept allows quantitative prediction of a wide variety of 
biological endpoints for different radiation qualities.  
Methods: Clustering on the nanometer level is considered on 
the level of SSB and leads to an increased yield of DSB as a 
consequence of interaction of two SSB induced in the DNA 
within a short distance. Clustering at the micrometer level is 
taken into account by the distinction of two DSB classes, 
depending on the number of DSB induced within chromatin 
loops of about 2 Mbp size: isolated DSB (iDSB) corresponding 
to exactly one DSB/loop, and clustered DSB (cDSB) 
corresponding to more than one DSB/loop. Predictions of 
biological effects are solely based on the yields of iDSB and 
cDSB, respectively.  
Results: For high-LET radiation, the concept allows predicting 
the observed increased relative biological effectiveness (RBE) 
and its dependence on the ion species, LET, dose and cell 
type1,2 based on the knowledge of the corresponding photon 
dose response curves. Furthermore, the two classes of iDSB 
and cDSB can be identified with the two components leading 
to biphasic rejoining kinetics, and the model is able to 
correctly predict the fractions of fast and slow rejoining over 
a wide spectrum of different radiation qualities4.  
For high energetic photon radiation, the concept allows 
explaining the linear quadratic shape of the photon dose 
response curve and predicts a transition to a more linear 
shape at high doses3. The model also correctly reproduces 
dose rate effects after photon irradiation5. Furthermore the 
increased effectiveness of ultrasoft x-rays is predicted by the 
model as a consequence of the increased DSB yield6.  
Finally, based on the cell cycle dependent replication of 
chromatin loops the cell cycle dependent variation of 
radiosensitivity is reproduced. Based on the model 
parameters derived from normal cells, the different cell 
cycle dependent sensitivity of NHEJ-deficient and HR-
deficient cells is predicted by the model7.  
Conclusion: Using the LEM and the GLOBLE model it could be 
shown that the knowledge of the initial spatial DSB 
distribution pattern induced by low- and high-LET radiation 
allows accurate quantitative prediction of radiation effects 
for a wide variety of different radiation qualities and 
biological endpoints. The consistent and simultaneous 
applicability of the model framework to widespread 
radiobiologic phenomena is a strong support for the 
underlying assumptions.  
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Since some of the most modern ion therapy facilities are 
offering or considering the irradiation with alternative ion 
beams, beyond proton and carbon, it has raised new 
attention the need for a proper description of these beams, 
in order to exploit their use for specific applications. In 
particular, helium and oxygen beams are presently available 
in the research cave of the Heidelberg Ion therapy facility 
(HIT). 
We developed and integrated in TRiP98, our research 
treatment planning system, specific beam models for these 
ions, which have been validated experimentally on different 
levels. 
For the Helium beam a semiempirical model for dose 
deposition and fragmentation was implemented, by 
modification of algorithms conventionally used in space 
radiation transport studies, translated to the typical 
therapeutic range of energies [1]. 
For Oxygen beam, the standard transport model of TRiP98 
was tuned on recent attenuation experiments and the 
fragmentation cascade has been improved using the latest 
beam models of the low-lying ions. 
Several treatment planning tests have been performed, 
showing no universal indications but rather selective 
advantages of the different beams, and revealing for 
example a considerable convenience of using Helium beams 
in specific configurations [2], or proposing combination of 
different ions [3]. 
Experimental verification has been performed for both ion 
beams at the experimental room of HIT, analyzing different 
endpoints: basics physics data, delivered 3D physical dose 
distribution and biological effect. Monoenergetic and 
extended target irradiations of different extensions with 
single and double opposed fields have been verified. In the 
case of oxygen beams, considering that its main importance 
is related to a possible indication for partially hypoxic 
tumors, the biological verification was extended beyond the 
RBE weighted dose effect, but also including the OER effect.  
As previously obtained with carbon ions [4], the kill-painting 
method, allowing to restore an homogeneous survival level 
on a differently oxygenated target, was verified with oxygen 
beams. It is found that with the latter ion beams, for a 
partially hypoxic target an inversion of the relative profile 
occurs, as compared to a normoxic case, with a slightly 
reduced normal tissue damage for same  cell killing in the 
target than with  the carbon irradiation. 
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The demand for personalized medicine is increasing, and 
considering that the population suffering from chronic 
diseases (i.e. cancer, Alzeihmer) is continuously growing it is 
expected that the consumption of molecular diagnostic 
products and radiotherapeutics will continue to increase. In 
this scenario, TRIUMF and its fleet of proton accelerators 
ranging from 13 to 500 MeV is offering a unique environment 
for scientists to enable the production of isotopes with 
potential applications in molecular imaging or radiotherapy. 
A multidisciplinary program involving target design, isotope 
production and radiopharmaceutical chemistry has emerged 
in the Division of Life Sciences to facilitate and accelerate 
the translation from bench-to-bedside. 
A brief overview of the recent efforts related to the 
production and applications of medical isotopes at TRIUMF 
will be presented. Comprehensive studies have been 
conducted to improve the production of conventional PET 
isotopes by a better understanding of the physical 
phenomenon occurring inside the target during beam 
irradiation. Feasibility of the production, from liquid targets, 
of radiometals (i.e. 44Sc, 68Ga, 86Y and 89Zr) used in medical 
imaging has also been demonstrated. The results of the ITAP 
project, led by TRIUMF and including a consortium of 
institutions, on accelerator-based production of 99mTc will be 
discussed. It has been shown that a reliable commercial scale 
(TBq) production of 99mTc is achievable by using 100Mo coated 
tantalum targets at energies up to 24 MeV. Investigations on 
the production and isolation of the therapeutic isotope 211At 
and its imaging companion 209At will be mentioned.  
Novel radiolabeling strategies and technologies have recently 
emerged to prepare radiopharmaceuticals and will be 
discussed. Isotopic exchange reactions are getting popular to 
rapidly and efficiently synthesize PET imaging probes. Click 
chemistry is also representing an attractive approach to 
radiolabel molecules because of its simple process, short 
reaction times and clean product synthesis. Microfluidic 
devices bear great promises in the field of radiochemistry as 
it is expected that they will allow faster reaction rate, 
exquisite reaction selectivity, reduced reagent consumption, 
and possibly revisit the hot-lab concept. An overview of the 
tracer development performed at TRIUMF (e.g. cysteine 
transporter, angiogenesis) will be presented. 
Finally, within the framework of the MEDICIS-PROMED 
consortium, a collaboration between TRIUMF and the 
Institute of Translational Molecular Imaging (ITMI) at the 
University Hospital of Geneva and the Laboratory of 
Bioorganic Chemistry and Molecular Imaging at EPFL will soon 
take place. This presentation will conclude with a short 
summary of our ambitious project on the development of 
dual modality molecular probes for ovarian cancer and their 
preclinical validations in animal models. 
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Purpose: The main purpose of the present work is to evaluate 
the effects of gold nanoparticles (GNPs) in different sizes and 
concentrations on cancer cells which undergo treatment with 
photon therapy.  
